Minimizing Neurological Damage From Infant At-Birth Trauma With Moderate Whole-Body Cooling - Children's Hospital Boston Cincinnati Sub-Zero (CSZ) Medical, a division of CSZ Products, Inc. and the leader in the design and development of advanced patient temperature management solutions, today announced its inclusion in the implementation of a neonatal therapeutic hypothermia protocol by Children's Hospital Boston. The hospital was the first to offer the treatment in New England.
Source: www.medicalnewstoday.comBayer's Novel Anticoagulant Rivaroxaban Recommended For EU Approval - Venous Blood Clot Prevention After Elective Hip Or Knee Replacement Surgery The European Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the anticoagulant rivaroxaban (Xarelto�), taken as one tablet, once-daily, for the prevention of venous blood clots (deep vein thrombosis (DVT) and pulmonary embolism (PE)) in patients undergoing elective (planned) hip or knee replacement surgery.
Source: www.medicalnewstoday.comFDA Grants Pediatric Exclusivity For TOPAMAX� Ortho-McNeil Neurologics, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for TOPAMAX� (topiramate), based on studies submitted in response to a Written Request by the FDA to investigate the use of TOPAMAX in pediatric patients aged 1 to 24 months with partial onset seizures.
Source: www.medicalnewstoday.com
# posted by Network @ 9:00 AM
